Joshua Fitch, Senior Editor

The primary and all key secondary endpoints were met compared to cream vehicle in the phase 3 DELTA TEEN trial.

Application submission is based on positive phase 3 data that demonstrated improvement in patients with type 2 and 3 SMA receiving current standard of care.

As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The past year saw a number of approvals adding to the toolbox for atopic dermatitis, including new formulations that work in new mechanisms.

According to a new study, racial and ethnic disparities were evident when counseling on nutrition, lifestyle, and weight among children with high blood pressure measurements.

Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the severity of the current respiratory virus season and stresses the importance of vaccinations to protect against influenza, COVID-19, RSV, and more.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the January/February, 2025, issue of Contemporary Pediatrics.

Nurse practitioner Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN underscores how critical simple, but factual, conversations can be with parents when it comes to pediatric care.

The patient had increased her vape use recently, but did not disclose when she started, or how much she vaped.

From 1999 to 2022, a 24.2% decrease in infant mortality was observed in the US, however, SUID mortality rates increased by nearly 12% from 2020 to 2022.

The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months.

Based on recent reports, norovirus outbreaks in the 2024-2025 seasonal year is above the range reported from the 2012-2020 and 2021-2024 seasonal years.

Already approved in those aged 18 and older in the United States, Valneva has submitted label extension applications to the FDA for IXCHIQ use in adolescents aged 12 to 17 years.

Detectable TTE in children's urine were 'significantly higher' in homes with reported in-home cannabis smoking.

During the current cold and flu season, children have a higher risk of getting sick. The AAP has release tips and reminders for parents to help keep children comfortable and healthy.

Eligible schools have the opportunity to receive 2 cartons of epinephrine nasal spray for use in emergency situations to treat type I allergic reactions, including anaphylaxis.

"In aggregation with other robust observational studies, these results can inform the management of asthma and allergic rhinitis in this patient group," wrote the study authors.

"The greatest risk reductions were demonstrated in those who experienced obesity remission during childhood," stated study authors.

Robert Frenck, MD, offers several practical tips to use when discussing pediatric vaccination among vaccine-hesitant parents.

Principal investigator Lewis Romer, MD, of Johns Hopkins Medicine joined us to discuss the actively-recruiting MoD PAH trial, and explains the role the pediatrician can play in care and recruitment.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Susan Carnell, PhD, highlights the nuanced relationship between social media use and binge eating in adolescents, noting the importance of addressing addictive behaviors and seeking support when needed.

Read these quick comments from Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, and Bernard Cohen, MD, regarding the banning of red No. 3 from foods and ingested drugs.

The digestive enzyme cartridge is designed to mimic pancreatic lipase function.

A CDC report shows only 23% of U.S. teens get enough sleep, with disparities highlighting the need for targeted health interventions.

Across all years in the report, the CDC rated each physical activity trend with a color of red, indicating that trends are going in the "wrong direction."

Manufacturers who use red no. 3 in food and and ingested drugs will have until January 15, 2027 or January 18, 2028, respectively, to reformulate their products.

According to the report, several key dietary behaviors such as daily fruit or vegetable intake among high school students were trending in the wrong direction.

The lead clinical trial investigator for a phase 3 study of crinecerfont in pediatric CAH patients breaks down the December 2024 FDA approval.